Company Encyclopedia
View More
name
Luoxin Pharmaceutical
002793.SZ
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. It also offers medical treatment and health care services.
3.159 T
002793.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking134/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-38.08%E
    • Profit Margin-27.20%E
    • Gross Margin54.45%B
  • Growth ScoreC
    • Revenue YoY2.96%C
    • Net Profit YoY2.84%C
    • Total Assets YoY0.00%C
    • Net Assets YoY0.00%C
  • Cash ScoreD
    • Cash Flow Margin-367.67%D
    • OCF YoY2.96%C
  • Operating ScoreC
    • Turnover0.56C
  • Debt ScoreD
    • Gearing Ratio61.65%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Luoxin Pharmaceutical: The controlling shareholder has partially lifted the pledge of shares and re-pledged them

    Luoxin Pharmaceutical announced that its controlling shareholder, Luoxin Holdings, recently released the pledge of 102 million shares and pledged 101 million shares. The released pledged shares account for 43.23% of its shareholding ratio and 9.42% of the company's total share capital; the pledged shares account for 42.75% of its shareholding ratio and 9.31% of the company's total share capital. As of the announcement date, Luoxin Holdings and its concerted parties have cumulatively pledged 137 million shares, accounting for 56.83% of the shareholding ratio and 12.63% of the company's total share capital. This pledge has no substantial impact on the company

    Zhitong·
    SZ
    002793
    -0.56%
    Zhitong·
    SZ
    002793
    -0.56%

    Luoxin Pharmaceutical: Net profit in the third quarter was 5.2318 million yuan, a year-on-year increase of 102.96%

    Luoxin Pharmaceutical announced that its revenue for the third quarter was 646 million yuan, a year-on-year increase of 3.94%; net profit was 5.2318 million yuan, a year-on-year increase of 102.96%. Revenue for the first three quarters was 1.723 billion yuan, a year-on-year decrease of 8.37%; net profit was 22.9268 million yuan, a year-on-year increase of 108.64%

    Zhitong·
    SZ
    002793
    -0.56%
    Zhitong·
    SZ
    002793
    -0.56%

    The concept of innovative drugs continues to rebound, with GZBL and Luoxin Pharmaceutical both hitting the daily limit

    The concept of innovative drugs continues the rebound momentum from yesterday, with GZBL and Luoxin Pharmaceutical hitting the daily limit, Sanofi's stock rising over 10%, and Laimei Pharmaceutical, Hainan Haiyao, Guangshengtang, and Yifang Biotechnology also following suit

    Zhitong·
    SZ
    002793
    -0.56%
    SZ
    002424
    +5.94%
    Zhitong·
    SZ
    002793
    -0.56%
    SZ
    002424
    +5.94%

    Luoxin Pharmaceutical issued a profit warning, expecting a net profit attributable to the parent company of 22.7 million to 25.2 million yuan in the first three quarters, turning losses into profits

    According to the Zhitong Finance APP, Luoxin Pharmaceutical disclosed its performance forecast for the first three quarters of 2025. The company expects a net profit attributable to shareholders of the listed company to be between 22.7 million yuan and 25.2 million yuan, turning a profit; the net profit after deducting non-recurring gains and losses is expected to be between 4.7 million yuan and 5.9 million yuan

    Zhitong·
    SZ
    002793
    -0.56%
    Zhitong·
    SZ
    002793
    -0.56%

    Luoxin Pharmaceutical: Han Fengsheng resigns as board secretary, Jiang Ying takes over

    Luoxin Pharmaceutical announced that the secretary of the board, Han Fengsheng, has resigned due to a job transfer, and he will continue to serve in a position at the holding subsidiary after his resignation. The company held a board meeting on October 13, 2025, and decided to appoint Jiang Ying as the new secretary of the board, with a term until the end of the fifth board's term

    Zhitong·
    SZ
    002793
    -0.56%
    Zhitong·
    SZ
    002793
    -0.56%
    © 2025 Longbridge｜Disclaimer